Literature DB >> 20063208

Scleroderma lung disease.

Jérôme Le Pavec1, David Launay, Stephen C Mathai, Paul M Hassoun, Marc Humbert.   

Abstract

Pulmonary involvement is second in frequency only to esophageal involvement as a visceral complication of systemic sclerosis (SSc) and has surpassed renal involvement as the most common cause of death. Interstitial lung disease and pulmonary vascular disease, particularly pulmonary arterial hypertension, are the most commonly encountered types of lung involvement. Chronic aspiration, airway disease, neuromuscular weakness, extrinsic pulmonary restrictive pathology, pleural effusions, pneumothorax, and lung cancer cause clinically significant disease and occur commonly enough to be routinely considered in the assessment of the SSc patient with respiratory symptoms. Affected patients have a significantly worse prognosis than patients with SSc who are free of pulmonary involvement.

Entities:  

Mesh:

Year:  2011        PMID: 20063208     DOI: 10.1007/s12016-009-8194-2

Source DB:  PubMed          Journal:  Clin Rev Allergy Immunol        ISSN: 1080-0549            Impact factor:   8.667


  151 in total

1.  Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions.

Authors:  C P Denton; M Humbert; L Rubin; C M Black
Journal:  Ann Rheum Dis       Date:  2006-06-22       Impact factor: 19.103

Review 2.  Does interstitial lung disease predispose to lung cancer?

Authors:  Craig E Daniels; James R Jett
Journal:  Curr Opin Pulm Med       Date:  2005-09       Impact factor: 3.155

Review 3.  Interstitial lung disease and gastroesophageal reflux.

Authors:  A J Ing
Journal:  Am J Med       Date:  2001-12-03       Impact factor: 4.965

4.  Massive pulmonary edema and death after prostacyclin infusion in a patient with pulmonary veno-occlusive disease.

Authors:  S M Palmer; L J Robinson; A Wang; J R Gossage; T Bashore; V F Tapson
Journal:  Chest       Date:  1998-01       Impact factor: 9.410

5.  Intravenous cyclophosphamide therapy for systemic sclerosis. A single-center experience and review of the literature with pooled analysis of lung function test results.

Authors:  P Airò; E Danieli; G Parrinello; C M Antonioli; I Cavazzana; P Toniati; F Franceschini; R Cattaneo
Journal:  Clin Exp Rheumatol       Date:  2004 Sep-Oct       Impact factor: 4.473

6.  Sildenafil for pulmonary arterial hypertension associated with connective tissue disease.

Authors:  David B Badesch; Nicholas S Hill; Gary Burgess; Lewis J Rubin; Robyn J Barst; Nazzareno Galiè; Gerald Simonneau
Journal:  J Rheumatol       Date:  2007-11-01       Impact factor: 4.666

7.  Survival in pulmonary hypertension associated with the scleroderma spectrum of diseases: impact of interstitial lung disease.

Authors:  Stephen C Mathai; Laura K Hummers; Hunter C Champion; Fredrick M Wigley; Ari Zaiman; Paul M Hassoun; Reda E Girgis
Journal:  Arthritis Rheum       Date:  2009-02

8.  Age and risk of pulmonary arterial hypertension in scleroderma.

Authors:  Lionel Schachna; Fredrick M Wigley; Betty Chang; Barbara White; Robert A Wise; Allan C Gelber
Journal:  Chest       Date:  2003-12       Impact factor: 9.410

9.  Fibrosing alveolitis in systemic sclerosis. Bronchoalveolar lavage findings in relation to computed tomographic appearance.

Authors:  A U Wells; D M Hansell; M B Rubens; P Cullinan; P L Haslam; C M Black; R M Du Bois
Journal:  Am J Respir Crit Care Med       Date:  1994-08       Impact factor: 21.405

10.  The predictive value of appearances on thin-section computed tomography in fibrosing alveolitis.

Authors:  A U Wells; D M Hansell; M B Rubens; P Cullinan; C M Black; R M du Bois
Journal:  Am Rev Respir Dis       Date:  1993-10
View more
  14 in total

Review 1.  Systemic sclerosis--challenges for clinical practice.

Authors:  Zsuzsanna H McMahan; Laura K Hummers
Journal:  Nat Rev Rheumatol       Date:  2012-11-13       Impact factor: 20.543

2.  Macrophage migration inhibitory factor mediates hypoxia-induced pulmonary hypertension.

Authors:  Yinzhong Zhang; Arunabh Talwar; Donna Tsang; Annette Bruchfeld; Ali Sadoughi; Maowen Hu; Kennedy Omonuwa; Kai Fan Cheng; Yousef Al-Abed; Edmund J Miller
Journal:  Mol Med       Date:  2012-03-27       Impact factor: 6.354

3.  A case series of patients on chemotherapy with dyspnoea and pulmonary infiltrates.

Authors:  Khalil Ullah; Aine O'Reilly; Derek G Power; Terence M O'Connor
Journal:  BMJ Case Rep       Date:  2013-06-05

4.  Clinical phenotypes, hemodynamic characteristics and prognosis of Chinese patients with systemic sclerosis-associated precapillary pulmonary hypertension: a retrospective study.

Authors:  Yu-Ping Yuan; Ping Yuan; Yi-Liang Su; Rong Jiang; Rui Zhang; Jing He; Hong-Ling Qiu; Ci-Jun Luo; Jin-Ming Liu; Su-Gang Gong; Lan Wang; Qin-Hua Zhao
Journal:  Clin Rheumatol       Date:  2022-01-31       Impact factor: 2.980

5.  NT-proBNP, hs-cTnT, and CRP predict the risk of cardiopulmonary outcomes in systemic sclerosis: Findings from the Canadian Scleroderma Research Group.

Authors:  Mayank Jha; Mianbo Wang; Russell Steele; Murray Baron; Marvin J Fritzler; Marie Hudson
Journal:  J Scleroderma Relat Disord       Date:  2021-09-03

6.  The Chinese herb Tripterygium wilfordii Hook F for the treatment of systemic sclerosis-associated interstitial lung disease: data from a Chinese EUSTAR Center.

Authors:  Luwei Yang; Qian Wang; Yong Hou; Jiuliang Zhao; Mengtao Li; Dong Xu; Xiaofeng Zeng
Journal:  Clin Rheumatol       Date:  2019-11-12       Impact factor: 2.980

7.  Relevance of partitioning DLCO to detect pulmonary hypertension in systemic sclerosis.

Authors:  Nadia Sivova; David Launay; Lidwine Wémeau-Stervinou; Pascal De Groote; Martine Remy-Jardin; Guillaume Denis; Marc Lambert; Nicolas Lamblin; Sandrine Morell-Dubois; Marie Fertin; Guillaume Lefevre; Vincent Sobanski; Olivier Le Rouzic; Pierre-Yves Hatron; Benoit Wallaert; Eric Hachulla; Thierry Perez
Journal:  PLoS One       Date:  2013-10-18       Impact factor: 3.240

8.  Blood-patch pleurodesis for pneumothorax in lung fibrosis due to progressive systemic sclerosis: A case report.

Authors:  Katsunori Kagohashi; Gen Ohara; Toshihiro Shiozawa; Tomohiro Tamura; Kunihiko Miyazaki; Koichi Kurishima; Hiroaki Satoh; Nobuyuki Hizawa
Journal:  Exp Ther Med       Date:  2014-09-29       Impact factor: 2.447

Review 9.  Personalized medicine in rheumatology: the paradigm of serum autoantibodies.

Authors:  Silvia Sirotti; Elena Generali; Angela Ceribelli; Natasa Isailovic; Maria De Santis; Carlo Selmi
Journal:  Auto Immun Highlights       Date:  2017-07-12

10.  Lung cancer and interstitial lung diseases: a systematic review.

Authors:  Kostas Archontogeorgis; Paschalis Steiropoulos; Argyris Tzouvelekis; Evangelia Nena; Demosthenes Bouros
Journal:  Pulm Med       Date:  2012-07-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.